<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:department>Sch of Pharmacy</gtr:department><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CD293334-DFCA-40C0-8441-A3BE6C7C33FF"><gtr:id>CD293334-DFCA-40C0-8441-A3BE6C7C33FF</gtr:id><gtr:name>Molecular Profiles Ltd</gtr:name><gtr:address><gtr:line1>1 Faraday Building  Nottingham Science &amp;</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:postCode>NG7 2QP</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7F482E98-A572-4714-AAA8-4C5389510425"><gtr:id>7F482E98-A572-4714-AAA8-4C5389510425</gtr:id><gtr:firstName>Jonathan</gtr:firstName><gtr:surname>Burley</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FG038740%2F1"><gtr:id>E75CEC17-3DF0-4B6B-BE15-849AC0179499</gtr:id><gtr:title>Constrained crystallisation for polymorph screening.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/G038740/1</gtr:grantReference><gtr:abstractText>Molecular compounds, including pharmaceuticals, can often adopt several crystal structures. These crystals, which contain the same molecules with different arrangements of the molecules in space, are known as polymorphs. An example would be for a u shaped molecule, which might be able to form the two polymorphs: uuuuuuu &amp;amp; ununun. Polymorphs are important as they can have different physical properties, despite containing exactly the same molecules. Solubility is one physical property that can differ between polymorphs, and is a critical parameter in controlling drug dosage. The pharmaceutical industry therefore screen all new drugs for polymorphism, and this screen is a requirement for getting the drug onto the market. Current state of the art screening methods require a significant amount of sample and significant amounts of time. This means that screening for polymorphism has to occur at a far later stage in the drug development pipeline than we would like.This research will look at a new method constrained crystallisation for screening compounds for polymorphism which requires far less compound (sub-milligram amounts rather than 10-50 grams) and less time (minutes rather than weeks). We will look at the use of in-situ Raman microscopy to characterise the polymorphs as they form, which will allow us to identify the polymorphs, understand how the molecules are linked together and to understand how one polymorph can transform into another. The recent development of new highly sensitive detectors for Raman microscopy, and the recent investment of 270k by the University of Nottingham in a world-class Raman microscope, are the key factors that enable this research. We will be working closely with Dr Graeme Day (Cambridge) to model the Raman spectra, and with Molecular Profiles (Nottingham) to develop constrained crystallisation to the level where it can be used in an industrial context.</gtr:abstractText><gtr:fund><gtr:end>2011-10-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2009-07-09</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>249047</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>We have been able to solve a long-standing conundrum about the recrystallisation of glassy paracetamol. This is a very well studied drug and the fact that different research groups were unable to replicate each others results for this simple compound indicated a hidden conflating variable in the various experimental approaches. We were able to show that on the *surface* the glassy material converts rapidly (hours) to crystalline form III, whereas in the *bulk* a slow (weeks) process leads to form II instead. While differences in *rate* between surface and bulk crystallisation had been seen previously, this was the first example discovered of differences in recrystallisation *pathway*.

We also were able to use the methods developed for the above to investigate the &amp;quot;Kofler melt&amp;quot; process for discovery of new co-crystals. We mapped the local concentrations of drugs in a Kofler melt preparation and were able to demonstrate that the range of accessible compositions was likely in all cases to be much lower than than expected.</gtr:description><gtr:exploitationPathways>See citations of the work.</gtr:exploitationPathways><gtr:id>ED0AC532-0B97-4C80-AF30-CE3971A21572</gtr:id><gtr:outcomeId>56c72dd5ba7c43.66371958</gtr:outcomeId><gtr:sectors><gtr:sector>Chemicals,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>6DD51912-4F9A-4B4C-AD56-45D1469CF0F4</gtr:id><gtr:title>Confocal Raman Microscope Mapping of a Kofler Melt</gtr:title><gtr:parentPublicationTitle>Crystal Growth &amp; Design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52d2ea78c171f3096dd71f20218b66af"><gtr:id>52d2ea78c171f3096dd71f20218b66af</gtr:id><gtr:otherNames>Alkhalil A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>doi_53d0140148acafb6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>660B9A3F-E8B2-4DD8-85DB-653B3BDD19C8</gtr:id><gtr:title>Analysis of phase transitions in molecular solids: quantitative assessment of phonon-mode vs intra-molecular spectral data</gtr:title><gtr:parentPublicationTitle>RSC Adv.</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52d2ea78c171f3096dd71f20218b66af"><gtr:id>52d2ea78c171f3096dd71f20218b66af</gtr:id><gtr:otherNames>Alkhalil A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>doi_53d02e02e9107697</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF64724D-87A3-4461-AD2A-6904B753B65B</gtr:id><gtr:title>Solubility Advantage of Amorphous Drugs and Pharmaceutical Cocrystals</gtr:title><gtr:parentPublicationTitle>Crystal Growth &amp; Design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e2585a679536f529377f0900aebc86a"><gtr:id>2e2585a679536f529377f0900aebc86a</gtr:id><gtr:otherNames>Babu N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>doi_55f95d95d565009f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>491D4C18-A773-47E3-9650-923213E0CFB6</gtr:id><gtr:title>In situ Raman mapping for identifying transient solid forms</gtr:title><gtr:parentPublicationTitle>CrystEngComm</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3172aaab79a9314a757f64e5d8b8f2c5"><gtr:id>3172aaab79a9314a757f64e5d8b8f2c5</gtr:id><gtr:otherNames>Nanubolu J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>5675fb37d93c3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DEA1C29-FA09-436C-B297-FE85D40BD9E0</gtr:id><gtr:title>Investigating the recrystallization behavior of amorphous paracetamol by variable temperature Raman studies and surface Raman mapping.</gtr:title><gtr:parentPublicationTitle>Molecular pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b38c0934e42a63b5f26d583121ac4582"><gtr:id>b38c0934e42a63b5f26d583121ac4582</gtr:id><gtr:otherNames>Nanubolu JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1543-8384</gtr:issn><gtr:outcomeId>doi_55f95d95d56eac8e</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/G038740/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>FB535BD0-E265-4C0A-8532-32DCB83A3951</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Tools, technologies &amp; methods</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>98EA7556-1427-44F9-84F3-BF99B7207302</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Analytical Science</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>